Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmexa AS

Division of Affitech AS
www.pharmexa.com

Latest From Pharmexa AS

Appointments: Eli Lilly, Alexion, Actelion, Polyphor, Constellation, Bone Therapeutics and Allied Minds

This week's roundup includes the announced retirement of Lilly's CFO, high-level appointments by Alexion Pharmaceuticals, Actelion and Constellation, and board elections by Wilson Therapeutics, Bone Therapeutics and Atlantic Healthcare.

BioPharmaceutical Appointments

Phase III failure for pancreatic cancer vaccine hope GV1001

Hopes for what would have been the first therapeutic vaccine for pancreatic cancer have been dashed by the Phase III failure of KAEL-GemVax's GV1001, forcing the South Korean firm to reconsider the future strategy for its lead development project.

Cancer

KAEL-GemVax's GV1001 vaccine shows Phase II promise in lung cancer

A telomerase peptide oncovaccine being developed by the South Korean group KAEL-GemVax and already in a major Phase III programme for pancreatic cancer has also shown clinical promise in the treatment of non-small cell lung cancer (NSCLC).

Cancer Denmark

2011 Scrip Asia 100 - TeloVac tailwind helps KAEL-GemVax chart a course to market

Being part of a large listed group relieves KAEL-GemVax from the constant fundraising headaches typical of its peers, writes Ian Haydock. This article is part of the 2011 Scrip Asia 100.

Infectious Diseases Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • M&E Biotech AS
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Affitech AS
  • Senior Management
  • Achim Kaufhold, MD, PhD, CEO
    Claude Mikkelsen, SVP, Fin. & Investor Relations
    Mark J Newman, PhD, SVP, Research
    Dana Leach, PhD, SVP, Bus. Dev. & IP
  • Contact Info
  • Pharmexa AS
    Phone: (45) 45 16 25 25
    Agern Allé 1
    Hørsholm, DK-2970
    Denmark
Advertisement
Advertisement
UsernamePublicRestriction

Register